rf-fullcolor.png

 

July 3, 2012
by Alexander Gaffney, RAC

FDA Issues New Draft Guidance for Products Containing Acetaminophen

The US Food and Drug Administration (FDA) has released new draft guidance pertaining to over-the-counter drug products containing acetaminophen, saying it will allow exceptions to a labeling rule under limited circumstances.

Acetaminophen is commonly used in internal analgesic, antipyretic and antirheumatic (IAAA) drugs to relieve pain, but had also been associated with liver injury and stomach bleeding if used at high dosages. As a result of the associated adverse events, FDA required product manufacturers to label IAAA products with the following label as the result of a 2009 final rule:

Liver warning: This product contains acetaminophen.  Severe liver damage may occur if you take

    • More than [insert maximum number of daily dosage units] in24 hours, which is the maximum daily amount [optional: "for this product"]
    • With other drugs containing acetaminophen 
    • 3 or more alcoholic drinks every day while using this product.

Because the first clause of this statement can be construed as being confusing-FDA said it is aware of concerns saying it "might be interpreted as indicating that severe liver damage is associated with a total daily dose of acetaminophen that is less than 4,000 mg"-FDA said it will "exercise enforcement discretion" in certain circumstances.

If the manufacturer believes the use of the above statement could cause confusion as it relates to its specific product, FDA has authorized an alternate statement:

Liver warning:  This product contains acetaminophen. Severe liver damage may occur if you take:

    • More than 4,000 mg of acetaminophen in 24 hours
    • With other drugs containing acetaminophen
    • 3 or more alcoholic drinks every day while using this product.

While the changed wording was not authorized in the original regulation, FDA said its use of "enforcement discretion" is needed to mitigate "potential confusion." The alternate warning is not to be used for pediatric populations, which has a unique wording apart from the one in question.


Read more:

FDA - Guidance for Industry - Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use - Labeling for Products That Contain Acetaminophen

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.